Evidence map›Paper›PMID 36507264›Full record

ReviewFrontiers in bioengineering and biotechnology2022

Regenerative medicine applications: An overview of clinical trials.

Astgik Petrosyan, Paulo N Martins, Kim Solez, Basak E Uygun, Vijay S Gorantla, Giuseppe Orlando

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Oxytocin, the Love Hormone, in Stem Cell Differentiation.Current issues in molecular biology · 2024
    Review
  13. Review
  14. Pharmacotherapy for Keloids and Hypertrophic Scars.International journal of molecular sciences · 2024
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Silica nanoparticles in medicine: overcoming pathologies through advanced drug delivery, diagnostics, and therapeutic strategies.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 2 countries.

Astgik PetrosyanGOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics in Urology, Division of Urology, Children's Hospital Los Angeles, Saban Research Institute, Los Angeles, CA, United States.
Paulo N MartinsDepartment of Surgery, Transplant Division, UMass Memorial Medical Center, University of Massachusetts, Worcester, MA, United States.
Kim SolezDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Basak E UygunMassachusetts General Hospital, Shriners Hospitals for Children in Boston and Harvard Medical School, Boston, MA, United States.
Vijay S GorantlaWake Forest Baptist Medical Center and Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, United States.
Giuseppe OrlandoWake Forest Baptist Medical Center and Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, United States.
Atrium Health Wake Forest Baptist · USChildren's Hospital of Los Angeles · USForest Institute · USMassachusetts General Hospital · USUMass Memorial Medical Center · USUniversity of Alberta · CA

Funding

Recellularization of Liver BioscaffoldsR01DK084053 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI UYGUN, BASAK ELIF, YARMUSH, MARTIN L · 2009 to 2020
$4.6M
NIDDK NIH HHS R01 DK084053
6 · The paper itself

Abstract

Insights into the use of cellular therapeutics, extracellular vesicles (EVs), and tissue engineering strategies for regenerative medicine applications are continually emerging with a focus on personalized, patient-specific treatments. Multiple pre-clinical and clinical trials have demonstrated the strong potential of cellular therapies, such as stem cells, immune cells, and EVs, to modulate inflammatory immune responses and promote neoangiogenic regeneration in diseased organs, damaged grafts, and inflammatory diseases, including COVID-19. Over 5,000 registered clinical trials on ClinicalTrials.gov involve stem cell therapies across various organs such as lung, kidney, heart, and liver, among other applications. A vast majority of stem cell clinical trials have been focused on these therapies' safety and effectiveness. Advances in our understanding of stem cell heterogeneity, dosage specificity, and

Indexed as

bioengineeringCOVID-19extracellular vesiclesregenerative medicinestem cellstissue engineeringtransplantation

Identifiers

PMID36507264
PMCPMC9732032
OpenAlexW4310037440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.